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Background
In recent years, using MRI studies, researchers try to estab-
lish valid hypothesis about the role of hippocampus and
amygdala in schizophrenia.
Materials and methods
A critical presentation of meta-analyses and reviews of
MRI and post mortem studies in schizophrenic patients
that define the role of hippocampus and amygdala. Selec-
tive review of MRI and post-mortem studies between
1998-2005, including schizophrenic and bipolar patients,
in Medline. Preferential focus on review articles and meta-
analyses.
Results
Volume reductions of 5-8% are reported in 2/3 of the MRI
studies. However these findings are based on many stud-
ies including the hippocampus, but only a few studies of
amygdala. Therefore amygdala volume reductions can be
refuted by unpublished negative studies. The same con-
clusion can be drawn for postmortem studies; hippocam-
pal abnormalities are more robust than those of
amygdala.
Amygdala lesions result in emotional deficits, such as
facial affect recognition, that occurs also in schizophrenic
patients, especially paranoid, compared to non-paranoid.
The volume of amygdala may be inversely correlated with
the number of X chromosomes. Hippocampus lesions can
produce symptoms that resemble both the positive and
the negative symptoms of schizophrenia. However those
volume reductions are not specific findings of schizophre-
nia, since they are also found in bipolar patients and even
in normal elderly persons.
Conclusions
More studies, with larger sample sizes, are needed to
establish if schizophrenic patients possess reduced amy-
gdala volume. We list some of questions remaining to be
answered. First the specificity of the abnormality to schiz-
ophrenic patients and the possible relationship to specific
symptoms or cluster of symptoms. Another open domain
for research is whether structural abnormalities in schizo-
phrenia such as in hippocampus or amygdale represent a
possible genetic marker leading to a vulnerability disease
or is a non specific feature in the cohort of psychiatric
patients.
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